Spheroid Drug Screening
Spheroid Drug Screening - Related Videos
06:50
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
0 Views •
Cited by 1 •
2025
Here, we establish a metabolic profiling platform integrating three-dimensional (3D) glioma spheroids and imaging-based normalization via extracellular flux analysis. This approach enables more accurate assessment of tumor metabolic responses to drug treatments and provides insights into potential mechanisms of resistance.
05:54
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
0 Views •
Cited by 10 •
2018
Across a wide variety of disease indications, more physiologically relevant models are being developed and implemented into drug discovery programs. The new model system described here demonstrates how three-dimensional tumor spheroids can be cultured and screened in a high-throughput 1536-well plate-based system to search for new oncology drugs.
09:58
Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing
0 Views •
Cited by 37 •
2015
A protocol for robotic printing of cancer cell spheroids in a high throughput 96-well plate format using an aqueous two-phase system is presented.
06:40
A Robust Method for the Large-Scale Production of Spheroids for High-Content Screening and Analysis Applications
0 Views •
Cited by 4 •
2021
This protocol details a method for the production of three different types of spheroids in a manner that makes them suitable for large-scale high-content screening and analysis. In addition, examples are presented showing how they can be analyzed at spheroid and individual cell levels.
07:48
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
0 Views •
Cited by 20 •
2016
Identifying novel drug targets that transition from pre-clinical testing to human trials is a scientific priority. To that end, here we describe a functional genomics approach for examining the impact of gene depletion on cancer cell line spheroids, which more appropriately model human cancers in vivo.
FAQs
Gradients create unequal exposure conditions within the same spheroid. Cells near the exterior may experience greater access to oxygen, nutrients, and compounds, while interior regions face reduced diffusion and different physiological pressures. Consequently, a treatment can affect cellular zones unevenly, revealing responses that may be hidden when all cells are exposed more uniformly in two-dimensional culture.
These regions represent distinct cellular states within a single cancer model. A compound may reduce growth in proliferative areas yet have a different effect on quiescent or hypoxic cells. Examining changes in overall viability, structure, and growth therefore helps researchers determine whether an apparent response reflects broad activity or selective effects on particular parts of the spheroid.
Two-dimensional cultures generally lack the compact architecture, cell-cell interactions, and diffusion barriers produced by a three-dimensional aggregate. Spheroid Drug Screening incorporates these features, allowing treatment penetration and cellular responses to vary across the model. This added organization can provide a more informative context for studying tumor heterogeneity and drug resistance than measurements from a flat cell layer alone.
Researchers compare changes in spheroid growth, viability, and structure after exposure to therapeutic compounds. They can also examine differences in treatment response between candidate drugs or drug combinations. Considering several outcomes together is important because reduced growth does not necessarily describe every structural or viability change, while combined measurements provide a broader view of treatment effects.
Cells are first maintained under nonadherent or low-attachment conditions so they can self-assemble into compact spheroids. The resulting aggregates are then exposed to candidate compounds or combinations, followed by assessment of growth, viability, structure, and treatment response. Comparing these measurements across treatments enables researchers to identify differential activity in a tissue-like cancer model.
This approach is useful when researchers need to investigate tumor heterogeneity, drug resistance, or preclinical therapy selection in a model that includes three-dimensional cellular organization. Its diffusion barriers and distinct internal regions can expose treatment limitations that simpler cultures may not show. Results can support comparisons among candidate therapies and combinations before further cancer treatment evaluation.